Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating
Mizuho Securities Maintains Immunocore(IMCR.US) With Buy Rating
Immunocore Holdings: Outperform Rating With Promising Sales Growth and Strategic Advantages
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Immunocore Holdings (IMCR) Gets a Buy From BTIG
Immunocore Hldgs Analyst Ratings
Immunocore Holdings: Strong Kimmtrak Sales and Promising Pipeline Merit Buy Rating
Optimistic Buy Rating on Immunocore Holdings Amid Strong Kimmtrak Sales and Promising Oncology Pipeline
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $92
Barclays Gives a Buy Rating to Immunocore Holdings (IMCR)
Morgan Stanley Keeps Their Buy Rating on Immunocore Holdings (IMCR)
Immunocore Hldgs Analyst Ratings
Immunocore Hldgs Analyst Ratings
Immunocore Hldgs Analyst Ratings
Buy Rating Affirmed: Immunocore's Promising Survival Data and High Disease Control Rate in Advanced Melanoma
Buy Rating on Immunocore Holdings Backed by Promising Phase I/II Study Results and Potential T-cell Profile Benefits
Positive Outlook for Immunocore's KIMMTRAK Bolsters Buy Rating Amidst Advancing Clinical Trials
Immunocore Hldgs Analyst Ratings
Immunocore Hldgs Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)